Role of growth factors in pancreatic cancer

Murray Korc

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

Human pancreatic cancers overexpress a number of important tyrosine growth factor receptors and their ligands. These include the epidermal growth factor (EGF) receptor (EGFR) and related receptors, multiple ligands that bind to EGFR, certain fibroblast growth factors (FGF) receptors (FGFR) and ligands, and insulin-like growth factor I (IGF-I) and its receptor. The excessive activation of mitogenic signaling cascades that are modulated by these overexpressed ligands and receptors is compounded by the presence of mutations in the K-ras oncogene. Pancreatic cancers also overexpress transforming growth factor betas (TGF-β) that usually inhibit the growth of epithelial cells. Pancreatic cancers, however, underexpress the type 1 TGF- β receptor and harbor mutations in the smad4 gene, alterations that prevent TGF-βs from inhibiting cancer cell growth that do not confer onto pancreatic actions that promote cancer growth in vivo. Together, these perturbations confer onto pancreatic cancer cells a tremendous growth advantage.

Original languageEnglish (US)
Pages (from-to)25-41
Number of pages17
JournalSurgical Oncology Clinics of North America
Volume7
Issue number1
StatePublished - 1998
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Intercellular Signaling Peptides and Proteins
Ligands
Growth
Epidermal Growth Factor Receptor
Transforming Growth Factor beta
Fibroblast Growth Factor Receptors
IGF Type 1 Receptor
Mutation
ras Genes
Growth Factor Receptors
Tyrosine
Neoplasms
Epithelial Cells
Genes

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Role of growth factors in pancreatic cancer. / Korc, Murray.

In: Surgical Oncology Clinics of North America, Vol. 7, No. 1, 1998, p. 25-41.

Research output: Contribution to journalArticle

@article{814a267dd2034734a2058e20c65ff48d,
title = "Role of growth factors in pancreatic cancer",
abstract = "Human pancreatic cancers overexpress a number of important tyrosine growth factor receptors and their ligands. These include the epidermal growth factor (EGF) receptor (EGFR) and related receptors, multiple ligands that bind to EGFR, certain fibroblast growth factors (FGF) receptors (FGFR) and ligands, and insulin-like growth factor I (IGF-I) and its receptor. The excessive activation of mitogenic signaling cascades that are modulated by these overexpressed ligands and receptors is compounded by the presence of mutations in the K-ras oncogene. Pancreatic cancers also overexpress transforming growth factor betas (TGF-β) that usually inhibit the growth of epithelial cells. Pancreatic cancers, however, underexpress the type 1 TGF- β receptor and harbor mutations in the smad4 gene, alterations that prevent TGF-βs from inhibiting cancer cell growth that do not confer onto pancreatic actions that promote cancer growth in vivo. Together, these perturbations confer onto pancreatic cancer cells a tremendous growth advantage.",
author = "Murray Korc",
year = "1998",
language = "English (US)",
volume = "7",
pages = "25--41",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Role of growth factors in pancreatic cancer

AU - Korc, Murray

PY - 1998

Y1 - 1998

N2 - Human pancreatic cancers overexpress a number of important tyrosine growth factor receptors and their ligands. These include the epidermal growth factor (EGF) receptor (EGFR) and related receptors, multiple ligands that bind to EGFR, certain fibroblast growth factors (FGF) receptors (FGFR) and ligands, and insulin-like growth factor I (IGF-I) and its receptor. The excessive activation of mitogenic signaling cascades that are modulated by these overexpressed ligands and receptors is compounded by the presence of mutations in the K-ras oncogene. Pancreatic cancers also overexpress transforming growth factor betas (TGF-β) that usually inhibit the growth of epithelial cells. Pancreatic cancers, however, underexpress the type 1 TGF- β receptor and harbor mutations in the smad4 gene, alterations that prevent TGF-βs from inhibiting cancer cell growth that do not confer onto pancreatic actions that promote cancer growth in vivo. Together, these perturbations confer onto pancreatic cancer cells a tremendous growth advantage.

AB - Human pancreatic cancers overexpress a number of important tyrosine growth factor receptors and their ligands. These include the epidermal growth factor (EGF) receptor (EGFR) and related receptors, multiple ligands that bind to EGFR, certain fibroblast growth factors (FGF) receptors (FGFR) and ligands, and insulin-like growth factor I (IGF-I) and its receptor. The excessive activation of mitogenic signaling cascades that are modulated by these overexpressed ligands and receptors is compounded by the presence of mutations in the K-ras oncogene. Pancreatic cancers also overexpress transforming growth factor betas (TGF-β) that usually inhibit the growth of epithelial cells. Pancreatic cancers, however, underexpress the type 1 TGF- β receptor and harbor mutations in the smad4 gene, alterations that prevent TGF-βs from inhibiting cancer cell growth that do not confer onto pancreatic actions that promote cancer growth in vivo. Together, these perturbations confer onto pancreatic cancer cells a tremendous growth advantage.

UR - http://www.scopus.com/inward/record.url?scp=0031934765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031934765&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 25

EP - 41

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 1

ER -